Man Group plc Has $26.37 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Man Group plc decreased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 23.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,090,622 shares of the company’s stock after selling 340,933 shares during the quarter. Man Group plc’s holdings in Hims & Hers Health were worth $26,371,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of HIMS. Barclays PLC raised its position in Hims & Hers Health by 9.7% during the third quarter. Barclays PLC now owns 308,363 shares of the company’s stock valued at $5,680,000 after purchasing an additional 27,231 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Hims & Hers Health during the 4th quarter worth $445,000. Carnegie Investment Counsel lifted its position in shares of Hims & Hers Health by 25.5% during the 4th quarter. Carnegie Investment Counsel now owns 376,910 shares of the company’s stock worth $9,114,000 after buying an additional 76,650 shares during the last quarter. Lake Street Private Wealth LLC lifted its position in shares of Hims & Hers Health by 28.7% during the 4th quarter. Lake Street Private Wealth LLC now owns 133,168 shares of the company’s stock worth $3,220,000 after buying an additional 29,721 shares during the last quarter. Finally, Stonekeep Investments LLC boosted its stake in Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after buying an additional 882 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 11,581 shares of the business’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $29.26, for a total transaction of $338,860.06. Following the sale, the chief financial officer now owns 124,104 shares of the company’s stock, valued at $3,631,283.04. The trade was a 8.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 50,000 shares of the stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $36.39, for a total value of $1,819,500.00. Following the sale, the chief executive officer now directly owns 92,103 shares in the company, valued at $3,351,628.17. This trade represents a 35.19% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 563,973 shares of company stock worth $21,951,757. 13.71% of the stock is owned by company insiders.

Hims & Hers Health Stock Down 4.2%

Shares of HIMS opened at $58.54 on Friday. The stock has a market cap of $13.10 billion, a P/E ratio of 133.05 and a beta of 1.84. The business’s fifty day moving average is $34.85 and its 200 day moving average is $33.40. Hims & Hers Health, Inc. has a 12-month low of $13.47 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $586.01 million for the quarter, compared to analysts’ expectations of $535.21 million. During the same period in the previous year, the company earned $0.05 earnings per share. The firm’s revenue for the quarter was up 110.7% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Needham & Company LLC reissued a “buy” rating and set a $61.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 6th. TD Cowen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. Citigroup restated a “sell” rating and issued a $30.00 target price (up previously from $25.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Bank of America upped their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an “underperform” rating in a report on Tuesday, April 29th. Finally, Leerink Partners raised their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $37.67.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.